BIOE Bio Essence Corp revenue, earnings and financials

For the quarter ended June 30, 2026, Bio Essence Corp reported revenue of $795K (up 206.7% from a year earlier), net income of $270K and diluted EPS of n/a; over the last four quarters revenue was $2.91M and net income $1.52M; for the fiscal year ended December 2025 revenue was $1.90M, up 485.8% on the year before.

BIOE annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $1.90M, gross profit $1.43M, operating income $900K, net income $896K (margin 47.2%), EPS n/a
• Fiscal year ended Dec 2024: revenue $324K, gross profit $217K, operating income −$459K, net income −$1.31M (margin -404.0%), EPS −$0.03
• Fiscal year ended Dec 2023: revenue $552K, gross profit $277K, operating income −$346K, net income −$972K (margin -176.2%), EPS −$0.03
• Fiscal year ended Dec 2022: revenue $622K, gross profit $328K, operating income −$511K, net income −$810K (margin -130.3%), EPS −$0.02
• Fiscal year ended Dec 2021: revenue $888K, gross profit $298K, operating income −$858K, net income −$648K (margin -72.9%), EPS −$0.02

BIOE quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $795K (up 206.7% year over year), net income $270K, EPS n/a
• Quarter ended Mar 31, 2026: revenue $501K (up 2155.8% year over year), net income $205K, EPS n/a
• Quarter ended Dec 31, 2025 (from the annual report): revenue $1.48M, net income $1.03M, EPS n/a
• Quarter ended Sep 30, 2025: revenue $137K (up 1.6% year over year), net income $13.0K, EPS n/a
• Quarter ended Jun 30, 2025: revenue $259K (up 521.5% year over year), net income $59.9K, EPS $0.00
• Quarter ended Mar 31, 2025: revenue $22.2K, net income −$206K, EPS −$0.01
• Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$27.6K, EPS $0.01
• Quarter ended Sep 30, 2024: revenue $135K (down 13.5% year over year), net income −$1.20M, EPS −$0.03
• Quarter ended Jun 30, 2024: revenue $41.7K (down 83.9% year over year), net income −$216K, EPS −$0.01
• Quarter ended Mar 31, 2024: revenue n/a, net income $134K, EPS $0.00
• Quarter ended Dec 31, 2023 (from the annual report): revenue −$205K (down 24.3% year over year), net income −$194K, EPS $0.00
• Quarter ended Sep 30, 2023: revenue $156K (down 18.9% year over year), net income −$315K, EPS −$0.01
• Quarter ended Jun 30, 2023: revenue $260K (down 9.9% year over year), net income −$285K, EPS −$0.01
• Quarter ended Mar 31, 2023: revenue $341K (up 11.4% year over year), net income −$179K, EPS −$0.01
• Quarter ended Dec 31, 2022 (from the annual report): revenue −$165K (down 177.5% year over year), net income −$213K, EPS $0.00
• Quarter ended Sep 30, 2022: revenue $192K (down 15.4% year over year), net income −$199K, EPS −$0.01
• Quarter ended Jun 30, 2022: revenue $288K (up 22.1% year over year), net income −$164K, EPS $0.00
• Quarter ended Mar 31, 2022: revenue $306K (up 44.5% year over year), net income −$233K, EPS −$0.01
• Quarter ended Dec 31, 2021 (from the annual report): revenue $213K, net income −$90.6K, EPS $0.00
• Quarter ended Sep 30, 2021: revenue $227K, net income −$183K, EPS −$0.01

BIOE cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $1.57M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow $624K, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$1.03M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$703K, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$1.29M, share buybacks n/a

BIOE balance sheet

• Jun 30, 2026: cash n/a, total assets $4.00M, total liabilities $1.66M, shareholders' equity $2.34M
• Mar 31, 2026: cash n/a, total assets $789K, total liabilities $2.22M, shareholders' equity −$1.43M
• Dec 31, 2025: cash n/a, total assets $422K, total liabilities $2.50M, shareholders' equity −$2.07M
• Sep 30, 2025: cash $28.7K, total assets $185K, total liabilities $3.29M, shareholders' equity −$3.10M
• Jun 30, 2025: cash n/a, total assets $113K, total liabilities $3.23M, shareholders' equity −$3.11M
• Mar 31, 2025: cash n/a, total assets $366K, total liabilities $3.54M, shareholders' equity −$3.17M
• Dec 31, 2024: cash $1.37K, total assets $281K, total liabilities $3.25M, shareholders' equity −$2.97M
• Sep 30, 2024: cash $29.8K, total assets $716K, total liabilities $3.66M, shareholders' equity −$2.94M

What is BIOE's revenue?

Bio Essence Corp reported $2.91M of revenue over its last four quarters, through June 30, 2026.

Is BIOE profitable?

Yes. Bio Essence Corp earned $1.52M over the last four quarters.

BIOE ownership and insider trades · All stocks